Status:
TERMINATED
Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer
Lead Sponsor:
NSABP Foundation Inc
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known whether celecoxib is effective in preventing polyps in patients with col...
Detailed Description
OBJECTIVES: Primary * Compare celecoxib vs placebo, in terms of decreasing the incidence of adenomatous polyps of the colon and rectum, in patients with resected stage I adenocarcinoma of the colon....
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed adenocarcinoma of the colon
- Stage I disease
- Distal border of tumor ≥ 12 cm from the anal verge
- Tumor completely resected within the past 90 days
- Must have undergone a preoperative or postoperative colonoscopy to the cecum (or small bowel anastomosis) within the past 90 days
- All observed polyps must have been removed
- Patients with a history suggestive of hereditary non-polyposis colorectal cancer (HNPCC) must have a normal microsatellite instability status by immunohistochemistry or polymerase chain reaction
- Patients with family history of colon cancer who have not been diagnosed with HNPCC are eligible
- No prior familial adenomatous polyposis
- No prior invasive cancer or carcinoma in situ of the colon or rectum
- No clinical or radiologic evidence of metastatic disease
- PATIENT CHARACTERISTICS:
- Age
- 18 and over
- Performance status
- Zubrod 0-1
- Life expectancy
- At least 10 years
- Hematopoietic
- Complete blood count normal
- Platelet count normal
- Hepatic
- Aspartate aminotransferase (AST) normal
- Bilirubin normal
- Alkaline phosphatase normal
- Renal
- Creatinine normal
- Cardiovascular
- No active ischemic heart disease
- No New York Heart Association class III or IV heart disease
- No myocardial infarction within the past 6 months
- No symptomatic arrhythmia
- No symptomatic peripheral vascular disease or carotid disease that would preclude study participation
- Pulmonary
- No aspirin-sensitive asthma
- Gastrointestinal
- No history of inflammatory bowel disease
- No history of upper gastrointestinal bleeding
- No history of duodenal or gastric ulcer
- Other
- No known hypersensitivity to any COX-2 inhibitor, NSAIDs, aspirin, or sulfonamides
- No non-colorectal malignancy within the past 5 years except carcinoma in situ of the cervix, melanoma in situ, or basal cell or squamous cell skin cancer
- No other disease that would preclude study participation
- No psychiatric disorders, including history of clinical depression or addictive disorders, that would preclude giving informed consent or long-term compliance
- No rheumatologic or skeletal disorders requiring chronic NSAIDs or steroid therapy
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- PRIOR CONCURRENT THERAPY:
- Biologic therapy
- Not specified
- Chemotherapy
- Not specified
- Endocrine therapy
- Not specified
- Radiotherapy
- Not specified
- Surgery
- See Disease Characteristics
- Other
- No other concurrent investigational agents for colon cancer
- No concurrent chronic use of other cyclo-oxygenase-2 (COX-2) inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), or salicylates (e.g., aspirin)
- Chronic use is defined as use for more than an average of 3 days per month
- Concurrent NSAIDs allowed for up to 10 consecutive days for temporary relief due to inflammatory syndromes, injury, or postoperative pain
- Cardioprotective doses of aspirin (≤ 81 mg/day or 325 mg every other day) allowed
- No concurrent fluconazole or lithium
Exclusion
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00087256
Start Date
July 1 2004
End Date
April 1 2006
Last Update
January 7 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15215